Trial Profile

A Global Phase III Clinical Trial to Evaluate Ustekinumab Biosimilar Candidate (NeuLara )

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Inflammatory bowel diseases; Plaque psoriasis
Focus Registrational; Therapeutic Use
Sponsors NeuClone

Most Recent Events

23 Oct 2020 New trial record
20 Oct 2020 According to a NeuClone media release, the company is on track for this global Phase III trial starting in 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com